Each year, it is estimated more than 40,000 people will be diagnosed with liver cancer – and those numbers are increasing.

Research led by the Department of General and Visceral Surgery, Faculty of Medicine, University of Freiburg, Germany has ...

Hepatitis B virus (HBV) infection is known to be associated with the risk of hepatocellular carcinoma (HCC), but how and why ...

Compared with colorectal cancer (CRC) presenting as an isolated primary or second primary malignancy, CRC presenting ...

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

Objective Adhesion molecules play an important role in tumour metastasis. The liver is a frequent target for the metastasis of several tumour types. However, virtually no liver-specific adhesion ...

To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

A randomized study of sirolimus, a relatively new immunosuppressive agent, in 222 primary liver allograft recipients recruited from 23 centers in Australia, Europe, and North America, randomly ...